Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

Description

The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases

Conditions

Neoplasm Metastases, Metastases, Neoplasm

Study Overview

Study Details

Study overview

The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

Condition
Neoplasm Metastases
Intervention / Treatment

-

Contacts and Locations

Hamilton

RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, New Jersey, United States, 08690

Lakewood

RWJBarnabas Health - Monmouth Medical Center Southern Campus, Lakewood, New Jersey, United States, 08701

Livingston

RWJBarnabas Health - Saint Barnabas Medical Center, Livingston, New Jersey, United States, 10457

New Brunswick

Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States, 08901

New Brunswick

Cancer Institute of New Jersey, New Brunswick, New Jersey, United States, 08903

Somerset

RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset, New Jersey, United States, 08876

Toms River

RWJBarnabas Health - Community Medical Center, Toms River, New Jersey, United States, 08755

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have provided signed informed consent for the trial
  • * Aged ≥18 years at the time of informed consent
  • * Histologic proof of malignancy
  • * Radiologic or histologic evidence of bone metastases or non-bone metastases
  • * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≥3
  • * Pain Score ≥ 3
  • * Life expectancy of six months or more
  • * Willing and able to comply with all aspects of the protocol
  • * A female participant is eligible to participate if she is not pregnant and not breastfeeding
  • * Woman of childbearing potential who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.
  • * A male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment.
  • * Metastasis from a highly radiosensitive tumor (eg, lymphoma, myeloma, germ cell tumor)
  • * Spinal metastasis
  • * Active compression of spinal cord/cauda equina
  • * Previous RT or SBRT to the same site
  • * \> 3 sites requiring radiation treatment

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Rutgers, The State University of New Jersey,

Matthew P Deek, MD, PRINCIPAL_INVESTIGATOR, Rutgers Cancer Institute of New Jersey

Study Record Dates

2024-04-01